Jukka Hintikka still remembers the moment one of the first participants in the study returned for a follow-up MRI: the liver scan showed a visible reduction in fat after just four months of taking a simple 2.8-gram fiber supplement. That small daily dose of xylo-oligosaccharides (XOS), a prebiotic fiber, didn’t just shift numbers on a chart—it offered a glimpse of a new way to fight fatty liver disease, one of the most silent and widespread health threats of our time. Affecting about 75% of overweight adults, metabolic dysfunction-associated steatotic liver disease (MASLD) often creeps in unnoticed, with few symptoms until it progresses to cirrhosis or liver cancer. With lifestyle changes proving difficult to sustain, researchers have been searching for complementary tools—and this new clinical trial, led by scientists from the University of Jyväskylä and the University of Eastern Finland, suggests a promising ally in gut health.
The study, published in npj Gut and Liver, is the first to test XOS in humans with early fatty liver. Forty-two overweight adults took the supplement daily for four months. Using precise MRI scans, researchers measured liver fat before and after, while also analyzing blood and stool samples to track metabolic shifts. The results revealed that XOS reduced levels of harmful metabolites—specifically those derived from amino acids—that are known to fuel liver fat buildup. These compounds, produced when gut bacteria ferment protein excessively, dropped significantly, especially in those whose microbiomes were already out of balance.
Crucially, the benefits weren’t uniform. People whose guts showed signs of microbial imbalance—marked by too much protein fermentation compared to carbohydrate fermentation—responded best. In this subgroup, XOS didn’t just improve liver markers; it also reduced visceral fat, the dangerous fat wrapped around internal organs. One participant, a 48-year-old teacher from Kuopio, lost 4.2% of her liver fat and 1.8 kilograms of visceral fat without changing her diet or exercise routine. Meanwhile, those with more advanced disease markers saw little to no improvement, underscoring the importance of timing and personalization.
“This study opens the door to microbiome-guided therapy,” says Hintikka. The findings echo earlier animal research but now offer human proof that reshaping gut fermentation can protect the liver. While larger trials are needed, the implications are clear: a simple, low-cost supplement could become part of a precision approach to metabolic health. For millions living with early fatty liver, the future may not require a drastic overhaul—just a small spoonful of fiber, tailored to the trillions of microbes within.